Due to the approval of the KRASG12C inhibitor AMG 510 in KRASG12C NSCLC by the FDA, studies have been investigating the effect of the combination of KRAS inhibitors and ICIs at the bench and in clinics. This evidence concerns the gene KRAS and non-small cell lung carcinoma.